Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as AZD8630 (test formulation) via test inhaler
AZD8630 via test inhaler · 1 trial · 1 indication
To evaluate the relative bioavailability of AZD8630 test device compared to AZD8630 Monodose device.
| Arm | Type | Description |
|---|---|---|
| Sequence 1 (Treatment A- Treatment B) | EXPERIMENTAL | Participants will receive Treatment A (AZD8630 Monodose inhalation powder) crossover to Treatment B (AZD8630 test inhalation powder) |
| Sequence 2 (Treatment B- Treatment A) | EXPERIMENTAL | Participants will receive Treatment B (AZD8630 test inhalation powder) crossover to Treatment A (AZD8630 Monodose inhalation powder) |
| Name | Type | Description |
|---|---|---|
| AZD8630 (test formulation) via test inhaler | DRUG | Participants will receive AZD8630 via test inhaler. |
| AZD8630 (reference formulation) via Monodose inhaler | DRUG | Participants will receive AZD8630 via Monodose inhaler. |
| Test inhaler | DEVICE | Participants will receive AZD8630 via test inhaler. |
| Monodose inhaler | DEVICE | Participants will receive AZD8630 via Monodose inhaler. |
Inclusion Criteria: * Provision of signed and dated, written informed consent prior to any study specific procedures. * Healthy participants aged 18-55 years with suitable veins for cannulation or repeated venipuncture. * Females participants of childbearing potential must not be lactating and, if ...
AZD8630 via test inhaler is an investigational small molecule drug candidate developed by AstraZeneca PLC (ticker AZN). It is delivered by inhalation and has been studied in a Phase 1 clinical trial in healthy participants. The specific therapeutic indication for this asset has not been disclosed.
AZD8630 via test inhaler is developed by AstraZeneca PLC, which trades under the ticker AZN. AstraZeneca is the sponsor of the clinical program evaluating this inhaled small molecule formulation.
AZD8630 via test inhaler is in Phase 1 development. It is an investigational drug candidate and is not approved for any indication. One Phase 1 trial has been completed, and no active trials are currently listed for this asset.
AZD8630 via test inhaler has been evaluated in one completed Phase 1 trial, NCT06531811, titled a study to investigate the relative bioavailability of AZD8630 following a device and formulation transition in healthy participants. The trial enrolled 32 healthy volunteers in the United States and was randomized and controlled.
Yes. AZD8630 via test inhaler is also known as AZD8630 (test formulation) via test inhaler. Both names refer to the same AstraZeneca inhaled small molecule drug candidate studied in the completed Phase 1 trial NCT06531811.
The completed Phase 1 trial NCT06531811 studied the relative bioavailability of AZD8630 following a device and formulation transition in healthy participants. It enrolled 32 participants aged 18 years and older in the United States, was randomized and controlled, and did not use a double-blind design.